EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

The Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a marketing authorisation for Pomalidomide (Pomalidomide Celgene®) in the treatment of multiple myeloma for relapsed and refractory myeloma patients. The next step is for the European Commission to adopt the final licensing decision within three months. There is no doubt that this is a crucial step for patients within the EU towards getting access to pomalidomide in their national health systems.

Please see below links to the press release and summary of opinion published to that effect on the EMA website.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/05/news_detail_001804.jsp&mid=WC0b01ac058004d5c1







Recent news

» Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern Europe

» Horizon Europe research project looks to improve the affordability and sustainability of innovative health technologies

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy